Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly.
– According to KOLs, what are the most important unmet needs in PD? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2022?
– With five new product launches, three of which address the needs of advanced stage patients, which products are forecast to generate the highest sales over 2012-2022?
– What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
– An aging population is expected to increase prevalence of PD in all markets from 2012-2022. How will epidemiological changes impact the growth of the future PD market?
– What governmental developments are likely to affect reimbursement and generic erosion of PD drugs? What type of impact will this have on the markets covered over the forecast period?
– With five new product launches, three of which address the needs of advanced stage patients, which products are forecast to generate the highest sales over 2012-2022?
– What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
– An aging population is expected to increase prevalence of PD in all markets from 2012-2022. How will epidemiological changes impact the growth of the future PD market?
– What governmental developments are likely to affect reimbursement and generic erosion of PD drugs? What type of impact will this have on the markets covered over the forecast period?
Key Findings
– Population increases, especially in the elderly, will be a key driving force in the global PD market.
– With several small biotech and pharmaceutical companies involved in mid-stage development of PD products, there will be ample opportunity for partnerships with Big Pharma.
– Levodopa based therapy will remain the gold standard of care with advancements in administration, including the introduction of slow-release formulations and an emergency use inhaler.
– Several unmet needs are expected to remain after the forecast period, as advancements in the control of non-motor symptoms and in the development of disease-modifying therapies are lagging.
– With several small biotech and pharmaceutical companies involved in mid-stage development of PD products, there will be ample opportunity for partnerships with Big Pharma.
– Levodopa based therapy will remain the gold standard of care with advancements in administration, including the introduction of slow-release formulations and an emergency use inhaler.
– Several unmet needs are expected to remain after the forecast period, as advancements in the control of non-motor symptoms and in the development of disease-modifying therapies are lagging.
Scope
– Overview of Parkinson’s disease, including etiology, pathophysiology, motor and non-motor symptoms, and quality of life.
– Annualized Parkinson’s disease market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD market.
– Pipeline analysis: comprehensive data split across different Phases and emerging trends, specifically Newron’s safinamide, Biotie and UCB’s tozadenant, Civitas’ CVT-301, Impax’s Rytary (IPX066), Bial’s opicapone, Novartis’ mavoglurant (AFQ056), and Intec’s CD/LD-GR.
– Analysis of the current and future market competition in the global Parkinson’s disease market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
– Annualized Parkinson’s disease market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD market.
– Pipeline analysis: comprehensive data split across different Phases and emerging trends, specifically Newron’s safinamide, Biotie and UCB’s tozadenant, Civitas’ CVT-301, Impax’s Rytary (IPX066), Bial’s opicapone, Novartis’ mavoglurant (AFQ056), and Intec’s CD/LD-GR.
– Analysis of the current and future market competition in the global Parkinson’s disease market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Market News Analysis 